2 weeks Ago By ABMN Staff
Rhumbline Advisers bought a new stake in shares of Capricor Therapeutics Inc ( NASDAQ:CAPR – Free Report ) in the second quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor bought 30,886 shares of the biotechnology company’s stock, valued at approximately $147,000. Other institutional investors have also bought and sold shares of the company.
Vanguard Group Inc. lifted its position in Capricor Therapeutics by 17.2% in the first quarter.
Vanguard Group Inc. now owns 1,365,903 shares of the biotechnology company’s stock worth $9,274,000 after buying an additional 200,499 shares during the last quarter. Bank of New York Mellon Corp lifted its holdings in shares of Capricor Therapeutics by 12.
8% in the 2nd quarter. Bank of New York Mellon Corp now owns 79,782 shares of the biotechnology company’s stock worth $381,000 after acquiring an additional 9,040 shares during the last quarter. Finally, BNP Paribas Financial Markets bought a new stake in shares of Capricor Therapeutics in the 1st quarter worth about $40,000.
Institutional investors own 21.68% of the company’s stock. Insiders Place Their Bets In other Capricor Therapeutics news, major shareholder Shinyaku Co Ltd Nippon acquired 2,798,507 shares of the company’s stock in a transaction that occurred on Friday, September 20th.
The stock was bought at an average price of $5.36 per share, with a total value of $14,999,997.52.
Following the purchase, the insider now owns 7,090,351 shares in the company, valued at $38,004,281.36. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link .
12.00% of the stock is currently owned by corporate insiders. Wall Street Analysts Forecast Growth Read Our Latest Analysis on Capricor Therapeutics Capricor Therapeutics Stock Performance Capricor Therapeutics stock opened at $9.
95 on Monday. Capricor Therapeutics Inc has a fifty-two week low of $2.68 and a fifty-two week high of $12.
87. The company has a market cap of $318.19 million, a PE ratio of -11.
44 and a beta of 3.92. The business’s 50-day simple moving average is $4.
80 and its two-hundred day simple moving average is $5.30. Capricor Therapeutics ( NASDAQ:CAPR – Get Free Report ) last posted its earnings results on Wednesday, August 7th.
The biotechnology company reported ($0.35) EPS for the quarter, missing the consensus estimate of ($0.32) by ($0.
03). Capricor Therapeutics had a negative return on equity of 220.27% and a negative net margin of 102.
93%. The company had revenue of $3.97 million for the quarter, compared to analyst estimates of $4.
51 million. As a group, analysts predict that Capricor Therapeutics Inc will post -1.14 EPS for the current fiscal year.
Capricor Therapeutics Profile ( Free Report ) Capricor Therapeutics, Inc (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy. Further Reading Want to see what other hedge funds are holding CAPR? Visit HoldingsChannel.
com to get the latest 13F filings and insider trades for Capricor Therapeutics Inc ( NASDAQ:CAPR – Free Report ). Receive News & Ratings for Capricor Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Capricor Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter .
.
